- Home
- IOVA vs UDMY Comparison
IOVA vs UDMY Comparison
Compare IOVA & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- UDMY
- Stock Information
- Founded
- IOVA 2007
- UDMY 2009
- Country
- IOVA United States
- UDMY United States
- Employees
- IOVA N/A
- UDMY N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- UDMY Other Consumer Services
- Sector
- IOVA Health Care
- UDMY Real Estate
- Exchange
- IOVA Nasdaq
- UDMY Nasdaq
- Market Cap
- IOVA 1.0B
- UDMY 904.2M
- IPO Year
- IOVA N/A
- UDMY 2021
- Fundamental
- Price
- IOVA $1.75
- UDMY $6.77
- Analyst Decision
- IOVA Strong Buy
- UDMY Buy
- Analyst Count
- IOVA 9
- UDMY 11
- Target Price
- IOVA $15.50
- UDMY $9.90
- AVG Volume (30 Days)
- IOVA 13.9M
- UDMY 1.1M
- Earning Date
- IOVA 05-08-2025
- UDMY 04-30-2025
- Dividend Yield
- IOVA N/A
- UDMY N/A
- EPS Growth
- IOVA N/A
- UDMY N/A
- EPS
- IOVA N/A
- UDMY N/A
- Revenue
- IOVA $212,679,000.00
- UDMY $790,019,000.00
- Revenue This Year
- IOVA $182.20
- UDMY $2.96
- Revenue Next Year
- IOVA $62.10
- UDMY $5.52
- P/E Ratio
- IOVA N/A
- UDMY N/A
- Revenue Growth
- IOVA 11070.12
- UDMY 5.43
- 52 Week Low
- IOVA $2.70
- UDMY $5.68
- 52 Week High
- IOVA $13.60
- UDMY $10.61
- Technical
- Relative Strength Index (RSI)
- IOVA 23.78
- UDMY 48.84
- Support Level
- IOVA $3.02
- UDMY $6.21
- Resistance Level
- IOVA $3.31
- UDMY $7.06
- Average True Range (ATR)
- IOVA 0.24
- UDMY 0.27
- MACD
- IOVA -0.09
- UDMY 0.09
- Stochastic Oscillator
- IOVA 4.81
- UDMY 73.02
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.